Quest Diagnostics Outpaces Medical Sector as DGX Shows Stronger Momentum in 2026
Quest Diagnostics Outpaces Medical Sector as DGX Shows Stronger Momentum in 2026
Quest Diagnostics has drawn fresh investor attention in 2026 as shares of DGX appear to be performing better than many names in the broader medical sector. The discussion follows a Zacks/Yahoo Finance report asking whether medical stocks are lagging Quest Diagnostics this year.
DGX Gains Attention From Investors
Quest Diagnostics is one of the largest diagnostic information services companies in the United States. The company provides laboratory testing, clinical insights, and health data that help doctors, hospitals, employers, and patients make better medical decisions. According to Questâs investor materials, the company serves one in three adult Americans and works with about half of U.S. physicians and hospitals.
This wide reach gives DGX a strong position in the healthcare market. While many medical stocks have faced pressure from costs, reimbursement concerns, and mixed investor sentiment, Quest has benefited from steady demand for diagnostic testing and improved financial guidance.
Recent Financial Results Support the Bullish Case
Quest reported first-quarter 2026 revenue of $2.90 billion, up 9.2% from the prior year. Organic revenue growth reached 9.0%, showing that the companyâs core business remained healthy even without relying only on acquisitions. Adjusted diluted EPS rose 13.1% to $2.50.
These numbers helped strengthen confidence in DGX. The company also raised its full-year 2026 outlook, expecting revenue between $11.78 billion and $11.90 billion, while adjusted EPS is now expected between $10.63 and $10.83.
Why Quest Diagnostics May Be Ahead of Other Medical Stocks
One key reason Quest Diagnostics may be outperforming is the defensive nature of its business. Diagnostic testing is not a luxury product. Patients still need blood tests, pathology services, cancer screenings, infectious disease testing, and other lab services during many economic conditions.
Another factor is scale. Quest operates with a large national network, which can help control costs and improve efficiency. In healthcare, scale often matters because larger providers can spread technology, logistics, and administrative costs across a wider customer base.
DGX Stock Snapshot
As of the latest available market data, DGX traded around $193.64, with a market capitalization of about $21.7 billion. Its price-to-earnings ratio was about 21.4, based on the data available at the time.
Those figures suggest that investors are pricing Quest as a stable healthcare services company with consistent earnings power. While the valuation is not extremely cheap, the companyâs growth outlook and raised guidance may help explain why investors continue to watch DGX closely.
Comparison With DaVita
The Zacks-style comparison also places attention on other medical names such as DaVita. DaVita, which focuses on kidney dialysis services, reported first-quarter 2026 results with net income from continuing operations of $198 million and diluted EPS from continuing operations of $2.87.
DaVitaâs stock recently traded around $194.85, with a market capitalization near $13.4 billion and a price-to-earnings ratio of about 18.2.
Both companies operate in healthcare services, but their business models are different. Quest focuses on diagnostics and lab testing, while DaVita focuses mainly on dialysis care. This difference matters because investor expectations, growth drivers, and risks are not the same.
Market Takeaway
The main takeaway is that Quest Diagnostics appears to be standing out in the medical sector because of strong revenue growth, higher earnings, raised guidance, and steady demand for testing services. The companyâs broad role in the U.S. healthcare system gives it a durable business base.
However, investors should remember that healthcare stocks can still face risks. These may include changes in reimbursement rates, labor costs, regulation, acquisition integration, and competition. Even strong companies can see their share prices move sharply when market sentiment changes.
Conclusion
Quest Diagnostics has shown stronger momentum than many medical stocks so far in 2026. Its first-quarter results, improved guidance, and large diagnostic testing footprint support the view that DGX remains a key stock to watch in the healthcare services space. For investors comparing medical stocks, DGX stands out as a company with scale, stable demand, and improving earnings visibility.
#SlimScan #GrowthStocks #CANSLIM